Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on May 27, 2022. The report details the results of the Company's 2022 Annual Meeting of Stockholders held on the same date and the subsequent filing of a Certificate of Amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to increase the number of authorized common shares from 150,000,000 to 300,000,000. The Certificate of Amendment was filed with the Delaware Secretary of State on May 27, 2022.
- Director Elections: Stockholders elected three Class II directors (Alexis Borisy, Mark Murcko, Ph.D., and Laura Shawver, Ph.D.) for three-year terms ending in 2025.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation and set the frequency of future advisory votes to every one year.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, specific risks, or contingencies. It strictly reports on the voting outcomes of the Annual Meeting and the administrative filing of the share authorization amendment.
Key Facts for Investor Verification
- Verify the impact of the authorized share increase (doubling from 150M to 300M) on potential future dilution.
- Review the voting results for the election of directors, noting the number of votes withheld for each candidate.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2022 fiscal year.
- Check the Definitive Proxy Statement on Schedule 14A (filed April 14, 2022) for detailed background on the proposals and director biographies.